Pesticidal compositions and processes related thereto
US-9215870-B2 · Dec 22, 2015 · US
Processes for preparing ASK1 inhibitors
US9771328B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9771328-B2 |
| Application number | US-201715413154-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2017 |
| Priority date | Dec 23, 2014 |
| Publication date | Sep 26, 2017 |
| Grant date | Sep 26, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides processes for the preparation of a compound of formula: which exhibits apoptosis signal-regulating kinase (“ASK1”) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.
First claim
Opening claim text (preview).
What is claimed is: 1. Crystalline 5-(4-cyclopropyl-1H-imidazol-1-1-2-fluoro-4-methylbenzoic acid hydrochloride (Compound of formula (D-a) Form II) characterized by an X-ray powder diffractogram comprising the following peaks: 8.7, 12.1, 25.7, and 26.3° 2θ±0.2° 2θ, as determined on a diffractometer using Cu—K□ radiation at a wavelength of 1.5406 Å. 2. Compound of formula (D-a) Form II according to claim 1 , wherein the diffractogram comprises additional peaks at 17.3, 19.0, 22.4, 28.6, and 29.7° 2θ±0.2° 2θ. 3. Compound of formula (D-a) Form II according to claim 1 , wherein the diffractogram is substantially as shown in FIG. 4 . 4. Compound of formula (D-a) Form II according to claim 1 , characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 217° C. 5. Compound of formula (D-a) Form II according to claim 1 , wherein the DSC curve is substantially as shown in FIG. 5 .
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antihypertensives · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9771328B2 cover?
- The present disclosure provides processes for the preparation of a compound of formula: which exhibits apoptosis signal-regulating kinase (“ASK1”) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D233/64. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).